Advertisement

Topics

Contrasting fortunes for Duchenne rivals, as PTC fails and Sarepta soars

10:14 EDT 26 Oct 2017 | pharmaphorum

Two rivals in the emerging Duchenne muscular dystrophy (DMD) therapy area have experienced contrasting fortunes this week. Yesterday saw Sarepta increase its forecast for its full year revenues, up to between $150 and $155 million, thanks to bette...

Original Article: Contrasting fortunes for Duchenne rivals, as PTC fails and Sarepta soars

NEXT ARTICLE

More From BioPortfolio on "Contrasting fortunes for Duchenne rivals, as PTC fails and Sarepta soars"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...